Mary E. Maida. PhD : President and CEO

Dr. Maida's background includes Bachelor’s degrees in microbiology, finance, and operations management. She holds a Master's Degree in Neurobiology and Anatomy, and a Ph.D. in molecular neuroscience, each of which was earned at the University of Rochester School of Medicine and Dentistry, Rochester, N.Y. Prior to her return to medical school, Dr. Maida served as CFO for a privately held consulting firm involved in the development of shopping malls and other commercial properties throughout the United States. She established Clerisy Corp to provide medical professionals with the means to fully commercialize their privately held intellectual property (IP). The Company accomplishes this through in-licensing promising products, through securing Option Agreements on patented products, or by purchasing patents outright from the Inventor or Assignee.

In her roles as CEO of Clerisy Corp. and its affiliate, the Medingen Group LLC, Dr. Maida is able to successfully merge the disciplines of business and molecular medicine for the purpose of evaluating, developing and commercializing IP that provide novel solutions for patient and consumer needs that have been identified by the healthcare professionals and practitioners in global medical communities. By acquiring the rights to Clerisy’s flagship product line, Aromahaler® Nasal SoftStrips™, Dr. Maida has been able to work closely with Clerisy’s management team and healthcare practitioners to develop a line of products that span multiple therapeutic areas and medical disciplines, all of which address the current and emerging health and medical challenges facing the population. Because Dr. Maida also maintains an Adjunct Professorship at the University of Rochester School of Medicine and Dentistry, she is able to continually have her finger on the pulse of epidemic, endemic, and pandemic threats and then use this information to develop new products that will deliver specific medicants using Clerisy’s platform delivery device, Nasal SoftStrips™.

"Our goal is to commercialize a safe, effective, and responsible products that provide a novel, non-invasive solution to the most pressing challenges facing consumers and their healthcare providers. Nasal SoftStrips™ will expand the breadth of patient care, personal health maintenance, and potentially lead to better health outcomes. The advantage of Clerisy’s business model is that we provide a fully integrated approach to evaluating and developing products that address clearly defined needs identified by the medical community, and will result in ease of use, improved patient comfort, better patient compliance, optimized health outcomes, and acceptance by the medical community. The mission of Clerisy Corp is to create healthier futures for all adults through commercialization of valuable IP developed within the scientific, medical, and medical research communities that provide solutions which exceed the efficacy and safety of current treatment options.”